Clinical Trial

The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 6, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is evaluation of the potential neuroprotective effect of oral hesperidin and diosmin in reducing paclitaxel- induced peripheral neuropathy in the treatment of breast cancer patients.
Trial Details
NCT Number NCT06811220
Lead Sponsor Alexandria University
Conditions Breast Cancer
Enrollment 140 participants
Start Date 2025-01-27
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-06